Ascidian Successfully Completes Dose Escalation Phase of ACDN-01 for Stargardt Disease

Ascidian Completes Critical Phase of ACDN-01 Trial for Stargardt Disease

Ascidian Therapeutics, a pioneering biotechnology firm focused on innovative RNA therapies, has announced a significant milestone in its ongoing clinical trial for the treatment of Stargardt disease. The completion of the adult dose escalation segment of the Phase 1/2 STELLAR trial for the investigational drug ACDN-01 marks a key step forward in developing effective treatments for this degenerative eye condition.

Overview of the STELLAR Trial

The STELLAR trial is a multi-center and open-label phase that evaluates the safety and efficacy of ACDN-01, Ascidian's leading RNA editing therapeutic candidate. The trial aims to assess the potential of a single subretinal injection to ameliorate the effects of Stargardt disease and other related ABCA4 retinopathy conditions. Notably, it enrolled ten adult participants aged between 18 and 77, and the next phase will include pediatric subjects aged 12 years and above.

The findings from the completed adult segment of the trial will be shared during the American Society of Gene & Cell Therapy Annual Meeting on May 12, providing insights into the safety profile and effectiveness of ACDN-01.

Expanding to Pediatric Subjects

Alongside the adult study completion, Ascidian Therapeutics announced the expansion of the STELLAR trial to include pediatric subjects. This critical step provides an opportunity to assess ACDN-01's impact on a younger demographic, potentially enabling interventions at an earlier stage of the disease. This expansion reflects the company's commitment to exploring comprehensive treatment options for patients experiencing Stargardt disease.

Introduction of STARPATH Study

In addition to the STELLAR trial, Ascidian has initiated the STARPATH study. This observational study aims to collect data from adults and children aged five years and older, seeking to streamline future entry into ACDN-01 clinical trials. Participants will undergo genetic testing and high-resolution retinal imaging to evaluate their disease and determine suitability for upcoming trials. The STARPATH study represents a proactive approach to understanding Stargardt disease better and developing tailored interventions.

The Promise of ACDN-01

ACDN-01 stands out as a groundbreaking therapy that employs RNA exon editing to directly address the underlying genetic issues associated with Stargardt disease. By concentrating on RNA rather than DNA, ACDN-01 seeks to restore full-length ABCA4 protein function in patients without altering their genetic material or using foreign enzymes. This approach allows the drug to target the root causes of the disease effectively.

Dr. Michael Ehlers, the founder and CEO of Ascidian Therapeutics, emphasized the significance of ACDN-01: "This novel approach has the potential to transform how we treat the genetic basis of Stargardt disease. Our mission is to convert groundbreaking scientific insights into life-altering therapies for the families impacted by this condition. Today’s advancement is a substantial step towards achieving that vision."

The Importance of Addressing Stargardt Disease

Stargardt disease is the most prevalent form of inherited macular degeneration and affects around 30,000 individuals in the United States. This condition typically manifests in childhood or young adulthood due to mutations in the ABCA4 gene, leading to progressive retinal degeneration and vision loss. Current treatment options are limited, with no FDA-approved therapies available to date, emphasizing the urgent need for effective solutions.

Dr. Mark Pennesi, Chief Medical Officer at the Retina Foundation of Dallas, acknowledged the profound need for advancements in treatments targeting this complex disease. He remarked on the excitement surrounding the inclusion of pediatric participants, highlighting the potential for earlier interventions that could ultimately lead to better outcomes.

Ascidian Therapeutics is committed to advancing clinical research to make a tangible difference in the lives of Stargardt disease patients. The dual approach of the STELLAR and STARPATH studies exemplifies their dedication to developing next-generation therapies that meaningfully correct genetic disorders impacting visual health.

For further information about STELLAR and STARPATH trials, interested individuals can visit AscidianClinicalTrials.com or their main website at www.ascidian.com.